trastuzumab
astrazeneca,daiichi sankyo
['trastuzumab', 'bcsm']
 #asco22 #bcsm 5-month difference in both pfs and os with use of #trastuzumabderuxtecan vs physician choice chemo in her-2 low metastatic disease. 88% were also er+. 
radiation oncologist @MSKCancerCenter | #bcsm + #metastatic dz | #HSR #impsci | visiting scholar @PC3Innovation | #PeloASTRO ?? ?